Survival Outcomes at Three Years After Primary vs Interval Debulking in Advanced Ovarian Cancer: A Retrospective Study from Hasan Sadikin Hospital (2021)

Alce Everdien, Andi Kurniadi, Dini Pusianawati, Aisyah Shofiatun Nisa, Dadang Hawari Subhan


Abstract


Objective: Ovarian cancer is the third most prevalent malignancy among women in Indonesia. The 5-year survival rate is approximately 49%, with 68% of patients diagnosed at an advanced stage. Standard treatment involves debulking surgery, which is categorized into primary debulking surgery (PDS) and interval debulking surgery (IDS). This study aims to compare the survival outcomes of ovarian cancer patients treated with PDS versus IDS at Dr. Hasan Sadikin General Hospital (RSHS) during 2021.
Methods: A retrospective review of medical records was performed for ovarian cancer patients who underwent surgery at RSHS in 2021. Patients were classified according to the type of surgical management (PDS or IDS), and survival data were analyzed accordingly.
Result: A total of 46 patients were included, with 38 undergoing PDS and 8 undergoing IDS. The mean overall survival was 34.1 months for the PDS group and 27.5 months for the IDS group. Bivariate analysis showed no significant difference in survival between the two groups (HR: 1.810, p = 0.341; 95% CI: 0.53–6.13). However, age (HR: 0.950, p = 0.014; 95% CI: 0.91–0.99) and progression-free survival duration (HR: 0.788, p = 0.0001; 95% CI: 0.71–0.86) were identified as significant prognostic factors for overall survival.
Conclusion: The mean overall survival for patients undergoing primary debulking surgery (PDS) was higher than for those undergoing interval debulking surgery (IDS), although this difference was not statistically significant.

Angka Kelangsungan Hidup Tiga Tahun Setelah Debulking Primer vs Interval pada Kanker Ovarium Stadium Lanjut: Sebuah Studi Retrospektif di RSUP Hasan Sadikin (2021)

Abstrak
Tujuan: Kanker ovarium merupakan keganasan ketiga terbanyak pada wanita di Indonesia. Angka kelangsungan hidup 5 tahun sekira 49%, dengan 68% pasien datang pada stadium lanjut. Tatalaksana standar melibatkan operasi debulking yang diklasifikasikan menjadi operasi debulking primer (PDS) dan operasi debulking interval (IDS). Penelitian ini bertujuan untuk membandingkan hasil kelangsungan hidup pasien kanker ovarium yang diobati dengan PDS versus IDS di RSUP Dr. Hasan Sadikin (RSHS) selama tahun 2021.
Metode: Sebuah studi retrospektif dilakukan melalui tinjauan rekam medis pasien kanker ovarium yang menjalani tatalaksana bedah di RSHS pada tahun 2021. Pasien dikategorikan berdasarkan jenis tatalaksana bedah (PDS atau IDS), dan data kelangsungan hidup dianalisis.
Hasil: Sebanyak 46 subjek diikutsertakan, dengan 38 pasien menjalani PDS dan 8 pasien menjalani IDS. Rerata kelangsungan hidup keseluruhan adalah 34,1 bulan pada kelompok PDS dan 27,5 bulan pada kelompok IDS. Analisis bivariat tidak menunjukkan perbedaan signifikan dalam kelangsungan hidup antara kedua kelompok (HR: 1,810, p = 0,341; 95% CI: 0,53–6,13). Namun, usia (HR: 0,950, p = 0,014; 95% CI: 0,91–0,99) dan durasi kelangsungan hidup bebas progresi (HR: 0,788, p = 0,0001; 95% CI: 0,71–0,86) diidentifikasi sebagai faktor prognostik yang signifikan terhadap kelangsungan hidup keseluruhan.
Kesimpulan: Rata-rata kelangsungan hidup keseluruhan pasien yang menjalani operasi debulking primer (PDS) lebih tinggi daripada rata-rata kelangsungan hidup keseluruhan pasien yang menjalani operasi debulking interval (IDS), meskipun tidak signifikan secara statistik.

Kata kunci: Angka kelangsungan hidup; kanker ovarium; pembedahan debulking interval; pembedahan debulking primer


Keywords


ovarian cancer; primary debulking surgery; interval debulking surgery; overall survival

Full Text:

PDF

References


Chi DS, Berchuck A, Dizon DS, et al. Principles and Practice of Gynecologic Oncology, 7e: Lippincott Williams & Wilkins, a Wolters Kluwer bu 2017.

Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses. Obstetrics & Gynecology. 2016;128(5):e210–e226.

HOGI. Pedoman Nasional Pelayanan Kedokteran Kanker Ginekologi. 2018.

Cummings M, Nicolais O, Shahin M. Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction. Diagnostics (Basel). 2022;12(4).

Chiofalo B, Bruni S, Certelli C, et al. Primary debulking surgery vs. interval debulking surgery for advanced ovarian cancer: review of the literature and meta-analysis. Minerva Med. 2019;110(4):330–340.

Hudry D, Bécourt S, Scambia G, et al. Primary or Interval Debulking Surgery in Advanced Ovarian Cancer: a Personalized Decision-a Literature Review. Curr Oncol Rep. 2022;24(12):1661–1668.

Winarto H, Welladatika A, Habiburrahman M, et al. Overall Survival and Related Factors of Advanced-stage Epithelial Ovarian Cancer Patients Underwent Debulking Surgery in Jakarta, Indonesia: A Single-center Experience. Open Access Macedonian Journal of Medical Sciences. 2022;10(B):265–280.

Chase DM, Mahajan A, Scott DA, et al. Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review. Int J Gynecol Cancer. 2023;33(10):1602–1611.

Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. The Lancet. 2015;386(9990):249–257.

Vergote I, Tropé Claes G, Amant F, et al. Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer. New England Journal of Medicine.363(10):943–953.

Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol. 2006;103(3):1070–1076.

Dino Renaldy A, Bambang Sutrisna. The Outcomes of Primary Debulking Surgery and Neoadjuvant Chemotherapy in Advanced Ovarian Cancer. Indonesia Journal of Obstetrics and Gynecology. 2016;4:111–116.

Brand AH. Ovarian Cancer Debulking Surgery: A Survey of Practice in Australia and New Zealand. International Journal of Gynecological Cancer. 2011;21(2):230–235.

Jochum F, Dumas É, Gougis P, et al. Survival outcomes of primary vs interval cytoreductive surgery for International Federation of Gynecology and Obstetrics stage IV ovarian cancer: a nationwide population-based target trial emulation. American Journal of Obstetrics & Gynecology. 2025;232(2):194.e191–194.e111.

Song YJ. Prediction of optimal debulking surgery in ovarian cancer. Gland Surg. 2021;10(3):1173–1181.




DOI: http://dx.doi.org/10.24198/obgynia.v8i3.1003

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.


     
 

Creative Commons License
Indonesian Journal of Obstetrics & Gynecology Science is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License
  Web Analytics
  View My Stat